

30<sup>th</sup> October, 2025

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

Dear Sir/Madam,

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ('SEBI Listing Regulations')**

Pursuant to Regulation 30 of the SEBI Listing Regulations, the outcome of the Board Meeting held today on 30<sup>th</sup> October, 2025 are as follows:

1. Mr Umang Vohra (DIN: 02296740), Managing Director & Global Chief Executive Officer (MD & GCEO) expressed his intention to not seek re-appointment as Managing Director & Global Chief Executive Officer of the Company upon completion of his current term on 31<sup>st</sup> March, 2026.
2. As part of the Company's structured succession planning, Mr Achin Gupta (DIN: 09491674), Global Chief Operating Officer has been elevated and appointed as the Managing Director & Global Chief Executive Officer of the Company with effect from 1<sup>st</sup> April, 2026 for a term of 5 years up to 31<sup>st</sup> March, 2031, liable to retire by rotation. The appointment is subject to the approval of the shareholders.

Mr Achin Gupta (DIN: 09491674) has also been appointed as Additional Director of the Company with effect from 1<sup>st</sup> April, 2026.

A press release relating to change in managerial personnel of the Company is enclosed as 'Annexure - A' to this letter.

3. Ms Meera Vanjari, General Counsel (Designate) has been appointed as the Global General Counsel and Senior Management Personnel of the Company with effect from 1<sup>st</sup> April, 2026. She will succeed Mr AS Kumar, Global General Counsel and SMP, who will complete his term on 31<sup>st</sup> March 2026.

Details as required under the SEBI Listing Regulations read with SEBI Master Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated 11<sup>th</sup> November, 2024 have been disclosed in Annexure – B to this letter.

The Board meeting of the Company commenced today at 09:30 a.m. (IST) and concluded at 01:30 p.m. (IST).

Please take the above information on record.

Yours faithfully,  
**For Cipla Limited**

**Rajendra Chopra**  
**Company Secretary**

Prepared by: Pavankumar Yadav

## Annexure A

### **Achin Gupta to succeed Umang Vohra as Cipla MD & GCEO effective April 1, 2026 Achin Appointed as MD & GCEO Designate effective January 1, 2026**

**Mumbai, India, October 30, 2025:** Cipla Limited (BSE: 500087; NSE: CIPLA EQ; and hereafter referred to as "Cipla") today announced that it has elevated Achin Gupta, Global Chief Operating Officer, Cipla Limited to MD & GCEO effective April 1, 2026, for a term of 5 years. The appointment will be proposed to the shareholders for their approval. Achin has been appointed as MD & GCEO Designate from January 1<sup>st</sup>, 2026. Achin will succeed Umang Vohra who has served as the MD & GCEO of Cipla since 2016. This planned transition is in line with our succession process developed by the Board and Umang, ensuring continuity, stability, and a clear vision for the future.

Achin Gupta has been serving as the GCOO of the Company since February 2025, overseeing Commercial markets, API, Manufacturing, and Supply Chain. He joined Cipla in 2021 as the CEO of the One India business and has been an integral member of the Management Council. He has driven strong growth, expanded Cipla's reach in chronic therapies and underserved geographies, and strengthened its core operations. Under his leadership, the India business delivered market-leading profitability, modernized its retail force, and introduced consumer-focused innovations. Achin also forged strategic global partnerships, positioning Cipla as a preferred innovation-led collaborator. Achin holds a M Tech degree from IIT Delhi, specializing in Biochemical Engineering and Biotechnology and an MBA from IIM, Ahmedabad.

In over two decades of his career, Achin has built a strong track record as an entrepreneurial leader. Achin is known for building new frontiers and fostering a culture of purpose, innovation, and accountability.

Umang Vohra who joined Cipla in 2015 as Global Chief Financial & Strategy Officer and thereafter served as Cipla's MD & GCEO since 2016. Over the past decade, Umang has led Cipla through a period of effective transformation, guided by the company's purpose of *Caring for Life*. His leadership has been instrumental in driving strategic growth, financial performance, innovation, and operational excellence across the organization. Cipla strengthened its global lung leadership, AMR stewardship, advanced its digital and manufacturing capabilities, and invested in next-generation therapies. The company has consistently maintained top rankings across key geographies. Umang's tenure has been defined by a deep commitment to patient-centricity, sustainability, good governance, talent development and being an employer of choice, laying a strong foundation for Cipla's future.

**Speaking on the announcement, Dr YK Hamied, Chairman, Cipla Limited said,** "I thank Umang for his stewardship over the last ten years, his outstanding contributions and dedication to Cipla's purpose of *Caring for Life* and combining business with a humanitarian approach. We wish Umang continued success in his future career. We are pleased to welcome Achin Gupta as he steps into this role, and I am confident he will lead Cipla to its next phase of progress and growth.

**Speaking on the occasion, Umang Vohra (current MD & GCEO) said;** “My ten years at Cipla has been filled with immense pride in what we've built together. Guided by our purpose of *Caring for Life*, I have had the privilege of working with passionate teams who consistently put patients first and drive innovation across the business. I'm deeply grateful to our Chairman, Dr Y K Hamied, and the Board for their trust and support throughout this journey. As I prepare to hand over the reins, I'm confident that Achin Gupta will lead Cipla forward with vision and purpose. I look forward to supporting him and the leadership team to ensure a smooth transition.

**Achin Gupta (MD & GCEO Designate effective Jan 1, 2026) stated,** “It is an honour to be entrusted with the responsibility of leading Cipla as its next MD & GCEO. Cipla's legacy of purpose-driven innovation and patient-centric care is deeply inspiring, and I am committed to building on the strong foundation laid by Umang and the leadership team. Over the past few years, I've had the privilege of working closely with teams across the organization and witnessing firsthand the passion, resilience, and commitment that define Cipla. As we move forward, my focus will remain on driving sustainable growth, deepening our impact across markets, and continuing to innovate with purpose.

### **About Cipla**

Established in 1935, Cipla is a global pharmaceutical company focused on agile and sustainable growth, complex generics, and deepening portfolio in our home markets of India, South Africa, North America, and key regulated and emerging markets. Our strengths in the respiratory, anti-retroviral, urology, cardiology, anti-infective and CNS segments are well-known. Our 46 manufacturing sites around the world produce 50+ dosage forms and 1,500+ products using cutting-edge technology platforms to cater to our 74+ markets. Cipla is ranked 3rd largest in pharma in India (IQVIA MAT Mar'25), 2nd largest in the pharma prescription market in South Africa (IQVIA MAT Feb'25), and 4th largest by prescription for Generic inhalation products in the US Gx (IQVIA TRx MAT Mar'25). For almost nine decades, making a difference to patients has inspired every aspect of Cipla's work. Our paradigm-changing offer of a triple anti-retroviral therapy in HIV/AIDS at less than a dollar a day in Africa in 2001 is widely acknowledged as having contributed to bringing inclusiveness, accessibility, and affordability to the centre of the HIV movement. A responsible corporate citizen, Cipla's humanitarian approach to healthcare in pursuit of its purpose of 'Caring for Life' and deep-rooted community links wherever it is present make it a partner of choice to global health bodies, peers, and all stakeholders. For more, please visit [www.cipla.com](http://www.cipla.com), or click on [Twitter](#), [Facebook](#), [LinkedIn](#).

### **Media Contacts**

#### **Corporate Communications**

Heena Kanal

E-Mail: [CorpComm@cipla.com](mailto:CorpComm@cipla.com)

#### **Investor Relations**

Diksha Maheshwari

E-Mail: [Investor.Relations@cipla.com](mailto:Investor.Relations@cipla.com)

**Annexure B**

<b>DIN</b>	02296740
<b>Name of Director</b>	Mr Umang Vohra
<b>Reason for change viz. <del>appointment, resignation, removal, death or otherwise</del></b>	Mr Umang Vohra, Managing Director and Global Chief Executive Officer (MD&GCEO) has expressed his intention to not seek re-appointment as the Managing Director and Global Chief Executive Officer of the Company, upon completion of his current term on 31 <sup>st</sup> March, 2026.
<b>Date of <del>appointment / cessation &amp; term of appointment</del></b>	
<b>Brief Profile (in case of appointment)</b>	Not applicable
<b>Disclosure of relationships between directors (in case of appointment of a director).</b>	Not applicable
<b>Information as required pursuant to BSE circular with ref. no. LIST/COMP/ 14/ 2018- 19 dated 20<sup>th</sup> June 2018 and the NSE circular ref. no. NSE/ CML/ 2018/24 dated 20<sup>th</sup> June 2018.</b>	Not applicable

**Annexure B**

<b>DIN</b>	09491674
<b>Name of Director</b>	Mr Achin Gupta
<b>Reason for change viz. appointment, resignation, removal, death or otherwise</b>	The Board of Directors at its meeting held on 30 <sup>th</sup> October, 2025 has elevated and appointed Mr Achin Gupta as the Managing Director & Global Chief Executive Officer of the Company with effect from 1 <sup>st</sup> April, 2026 for a term 5 years up to 31 <sup>st</sup> March, 2031, liable to retire by rotation. The appointment is subject to the approval of the shareholders.
<b>Date of appointment / cessation &amp; term of appointment</b>	Mr Achin Gupta has also been appointed as an Additional Director of the Company with effect from 1 <sup>st</sup> April, 2026.
<b>Brief Profile (in case of appointment)</b>	<p>Achin Gupta has been serving as the Global Chief Operating Officer of the Company since February 2025. He joined Cipla in 2021 as the CEO of the One India business and has been an integral member of the Management Council. He has driven strong growth, expanded Cipla's reach in chronic therapies and underserved geographies, and strengthened its core operations. Under his leadership, the India business delivered market-leading profitability, modernized its retail force, and introduced consumer-focused innovations. Achin also forged strategic global partnerships, positioning Cipla as a preferred innovation-led collaborator.</p> <p>Achin holds a M Tech degree from IIT Delhi, specializing in Biochemical Engineering and Biotechnology and an MBA from IIM, Ahmedabad.</p> <p>In over two decades of his career, Achin has built a strong track record as an entrepreneurial leader. Achin is known for building new frontiers and fostering a culture of purpose, innovation, and accountability.</p>
<b>Disclosure of relationships between directors (in case of appointment of a director).</b>	None
<b>Information as required pursuant to BSE circular with ref. no. LIST/COMP/ 14/ 2018- 19 dated 20<sup>th</sup> June 2018 and the NSE circular ref. no. NSE/ CML/ 2018/24 dated 20<sup>th</sup> June 2018.</b>	Mr Achin Gupta is not debarred from holding the office of director by virtue of any SEBI order or any other such authority.

**Annexure B**

<b>Name</b>	Ms Meera Vanjari
<b>Reason for change viz. appointment, <del>resignation, removal, death or otherwise</del></b>	Appointment as Global General Counsel and SMP w.e.f. 1 <sup>st</sup> April, 2026.
<b>Date of appointment / <del>cessation</del> &amp; term of appointment</b>	Terms of appointment: Full-time employment
<b>Brief Profile (in case of appointment)</b>	<p>Ms Meera Vanjari has graduated in Arts and Law from St. Xavier’s College and Government Law College, Mumbai, India. Prior to joining Cipla, Meera served as Area Counsel and Member of the Business Advisory Committee (BAC) at Abbott Healthcare, India, where she was responsible for delivering legal objectives across Abbott’s India operations.</p> <p>Meera brings over three decades of rich global experience in leading Legal, Compliance, and Intellectual Property (IP) functions across organisations such as Glenmark, Johnson &amp; Johnson, Bunge, Kodak, Marico, and others. Her deep expertise in strategic legal advisory, complex litigation, and business-critical negotiations has enabled her to play a pivotal role in shaping legal policy for these global organisations.</p> <p>She is a proud recipient of several awards and accolades, including the “Outstanding Corporate Counsel – Pharmaceutical Sector Award” and inclusion in “India’s General Counsel Power List” issued by The Legal 500.</p>
<b>Disclosure of relationships between directors (in case of appointment of a director)</b>	Not applicable

**Annexure B**

<b>Name</b>	Mr AS Kumar
<b>Reason for change viz. appointment, resignation, removal, death or otherwise</b>	Completion of term as Global General Counsel and SMP on 31 <sup>st</sup> March 2026
<b>Date of <del>Appointment/re-appointment/cessation and terms of appointment/re-appointment</del></b>	
<b>Brief Profile (in case of appointment)</b>	Not applicable
<b>Disclosure of relationship between directors (in case of appointment of a director)</b>	Not applicable